Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

PHASE2TerminatedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Colorectal CancerColorectal Adenocarcinoma
Interventions
DRUG

Brivanib

800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.

DRUG

Irinotecan

180 mg/m\^2 by vein on Day 1 of a 14 day cycle.

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER